Skip to content

Association Between Non-alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Calcification

Association Between NAFLD and Coronary Artery Calcification

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01158066
Enrollment
120
Registered
2010-07-08
Start date
2011-08-31
Completion date
2012-03-31
Last updated
2011-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Calcification

Keywords

NAFLD, Calcium score, Liver Fat, Visceral fat, excessive visceral fat, excessive liver fat accumulation, Biomarkers of insulin resistance (HOMA), inflammation (CRP) and (MDA-Paraoxonase)

Brief summary

Coronary artery disease are 8 times more prevalent in patients with NAFLD then the general population and are being considered the most common cause of death. Cardiac CT is a reliable non invasive method in demonstrating Coronary Plaques. However the association between coronary artery calcium score (CAC) and NAFLD remains controversial

Detailed description

Coronary artery disease are 8 times more prevalent in patients with NAFLD that the general population and are being considered the most common cause of death. Cardiac CT is a reliable non invasive method in demonstrating Coronary Plaques. However the association between coronary artery calcium score (CAC) and NAFLD remains controversial. AIM: the aim is to evaluate the association between CAC score ( CT) and NAFLD (CT). the working hypothesis is that Beside the traditional risk factors including age, diabetes, NAFLD is also associated with moderate to high risk of CAD.

Interventions

PROCEDURECT Cardiac

the patient will undergo cardiac CT

Sponsors

Ziv Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients who will undergo cardiac CT for patients with low to intermediate risk for CAD

Exclusion criteria

* Patients with PCI or CABG will be excluded

Design outcomes

Primary

MeasureTime frameDescription
Total calcium score measurement1 monthtotal calcium score will be measured

Countries

Israel

Contacts

Primary ContactAssy Nimer, MD
assy.n@ziv.health.gov.il+97246828445

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026